US regulators are undertaking a priority review of MSD’s Keytruda for the treatment of adult and paediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Read More
Patients in England, Wales and Northern Ireland with a rare and aggressive type of skin cancer will get routine access to a new treatment option on the NHS after cost regulators waved through Merck and Pfizer’s Bavencio.
Read More
Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
Read More
Patients with Merkel Cell Carcinoma living in the UK are a step closer to getting early access to Merck and Pfizer’s avelumab after regulators assigned the drug Promising Innovative Medicines (PIM) status.
Read More
US regulators have agreed to undertake a priority review EMD Serono’s avelumab as a potential treatment for metastatic Merkel cell carcinoma (MCC), a rare and aggressive disease in which cancer cells form in the top layer of the skin, close to nerve endings.
Read More
Patients with Merkel cell carcinoma (MCC) are a step closer to having access to the first drug indicated for the disease after regulators in Europe validated a marketing application for Merck KGaA and Pfizer’s avelumab.
Read More
